September 2013 | Volume 27 Number 9
New Targets for Triple-Negative Breast CancerChristina I. Herold, MD, Carey K. Anders, MD With regard to potential research strategies relevant to the treatment of triple-negative breast cancer/basal-like breast cancer, potential targets include PTEN, INPP4B, PIK3CA, KRAS, BRAF, EGFR, FGFR1, FGFR2, IGFR1, KIT, MET, PDGFRA, and the HIF1-Î±/ARNT pathway. Many of these will be discussed further in this review article.
Commentaries on this article: Triple-Negative Breast Cancer in the Post-Genomic EraNicole Williams, MD, Lyndsay Harris, MD
Triple-Negative Breast Cancer: Not Entirely NegativeShannon Puhalla, MD
Peripheral T-Cell Lymphoma: New Therapeutic StrategiesAdam M. Petrich, MD, Steven T. Rosen, MD In this article we briefly review the labeled indications for new agents for cutaneous and peripheral T-cell lymphoma, focus on data from the last 1 to 2 years, and on data from ongoing clinical trials, with the hope that in doing so we can help elucidate difficult treatment decisions.
Commentaries on this article: Peripheral T-Cell Lymphoma: Time for a T-Cell–Centric Standard of CareShella Saint Fleur-lominy, MD, PhD, Catherine S. Diefenbach, MD.
Peripheral T-Cell Lymphoma: What’s the Role for Transplant?Jonathon B. Cohen, MD, MS, Christopher R. Flowers, MD, MS
Clinical Applications of The Cancer Genome Atlas Project (TCGA) for Squamous Cell Lung CarcinomaSiddhartha Devarakonda, MD, Daniel Morgensztern, MD, Ramaswamy Govindan, MD We summarize here key findings from the comprehensive analysis of squamous cell lung cancer by The Cancer Genome Atlas group and discuss the clinical implications of these findings.
Commentaries on this article: Squamous Cell Lung Cancer: Where Do We Stand and Where Are We Going?Fred R. Hirsch, MD, PhD
Do Oncogenic Drivers Exist in Squamous Cell Carcinoma of the Lung?Liza C. Villaruz, MD, Timothy F. Burns, MD, PhD, Mark A. Socinski, MD
Non-Secretory Myeloma: A Clinician’s GuideSagar Lonial, MD, Jonathan L. Kaufman, MD Numerous small series of patients suggest that the prognosis for non-secretory myeloma patients is likely no worse than the prognosis for patients with traditional secretory myeloma, and in some settings may be superior.
Commentaries on this article: Non-Secretory Myeloma: Clinical and Biologic ImplicationsRafael Fonseca, MD
Non-Secretory Myeloma: One, Two, or More Entities?Meletios A. Dimopoulos, MD, Efstathios Kastritis, MD, Evangelos Terpo, MD
TO PUT THAT INTO CONTEXT…
Advancing Patient-Centric Genomic MedicineJames L. Mulshine, MD Sorting out the clinical implications of genomic data is going to require extensive or perhaps remarkably extensive clinical correlations; obtaining these clinical data will require the cooperation of our patients.
HOW AN EXPERT APPROACHES IT
Management of Marginal Zone LymphomaRobin Reid, MD, Jonathan W. Friedberg, MD MZL comprises three different entities that require integration of clinical and pathologic features to make a diagnosis. Treatment is chosen and initiated on the basis of presentation, symptoms, and underlying subtype.
PRACTICE & POLICY
Oral Oncolytics: Part 2-Legislation Targeting Cost & Access, and Other Initiatives to Reduce CostsRobert Mancini, PharmD, Ali Mcbride, PharmD, MS We examine efforts to correct cost inequities of oral anti-cancer agents through legislation, and we look at further efforts to reduce the cost of oral chemotherapy via cycle management and waste reduction.
T1 High-Grade Bladder Cancer Recurring After BCG Therapy: Radical Cystectomy Is Still the Best ApproachPeter E. Clark, MD
T1 High-Grade Bladder Cancer Recurring After BCG Therapy: A Curative Alternative to Radical Cystectomy ExistsPhillip J. Gray, MD, William U. Shipley, MD, Jason A. Efstathiou, MD
Collision Renal Cell Papillary and Medullary Carcinoma in a 66-Year-Old ManElaine T. Lam, MD, Elizabeth R. Kessler, MD, Thomas W. Flaig, MD The patient is a 66-year-old male who presented to his primary care physician with a 3-week history of painless gross hematuria. He underwent a renal ultrasound that showed a left kidney mass.